General Information of Drug Transporter (DT)
DT ID DTD0030 Transporter Info
Gene Name SLCO1B3
Transporter Name Organic anion transporting polypeptide 1B3
Gene ID
28234
UniProt ID
Q9NPD5
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Rifampicin Approved Drug
DT Modulation Rifampicin inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 0.8 microM) [1]
Affected Drug/Substrate Amantinin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Rifampicin inhibits the transportation of Bosentan by SLCO1B3 (IC50 = 1.6 microM) [2]
Affected Drug/Substrate Bosentan Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B1
DT Modulation Rifampicin inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 1.5 microM) [1]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Rifampicin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 1.3 microM; Ki = 0.9 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Rifampicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 2.6 microM) [4]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Rifampicin inhibits the transportation of Sulfobromophthalein by SLCO1B3 (Ki = 5 microM) [5]
Affected Drug/Substrate Sulfobromophthalein Modulation Type Inhibition
Cell System Oocytes-OATP1B3
DT Modulation Rifampicin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Rifampicin inhibits the transportation of Sincalide by SLCO1B3 [7]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Rifampicin inhibits the activity of SLCO1B3 [5], [8]
Exogenous Factor Paclitaxel Approved Drug
DT Modulation Paclitaxel inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 2 microM) [1]
Affected Drug/Substrate Amantinin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Paclitaxel inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 4 microM) [1]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Paclitaxel inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 0.5 microM) [4]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Paclitaxel inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Paclitaxel inhibits the transportation of Fluorescein by SLCO1B3 [9]
Affected Drug/Substrate Fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B1
DT Modulation Paclitaxel inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
DT Modulation Paclitaxel inhibits the activity of SLCO1B3 [10]
Exogenous Factor Cyclosporine Approved Drug
DT Modulation Cyclosporine inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 0.3 microM) [1]
Affected Drug/Substrate Amantinin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Cyclosporine inhibits the transportation of Bosentan by SLCO1B3 (IC50 = 0.8 microM) [2]
Affected Drug/Substrate Bosentan Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B1
DT Modulation Cyclosporine inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 0.3 microM) [1]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Cyclosporine inhibits the transportation of Rosuvastatin by SLCO1B3 (IC50 = 0.06 microM) [11]
Affected Drug/Substrate Rosuvastatin Modulation Type Inhibition
Cell System Human cervical cancer cell line (Hela)-OATP1B3
DT Modulation Cyclosporine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Dioscin Investigative Drug
DT Modulation Dioscin inhibits the transportation of Cyclosporine by SLCO1B3 [12]
Affected Drug/Substrate Cyclosporine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Dioscin inhibits the transportation of Epigalocatechin gallate by SLCO1B3 [12]
Affected Drug/Substrate Epigalocatechin gallate Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Dioscin inhibits the transportation of Rifampicin by SLCO1B3 [12]
Affected Drug/Substrate Rifampicin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Dioscin inhibits the transportation of Telmisartan by SLCO1B3 [12]
Affected Drug/Substrate Telmisartan Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Bromsulphthalein Investigative Drug
DT Modulation Bromsulphthalein inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 3 microM) [1]
Affected Drug/Substrate Amantinin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Bromsulphthalein inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 1.4 microM; Ki = 1 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Bromsulphthalein inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 [13]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Exogenous Factor MK-571 Discontinued Drug
DT Modulation MK-571 inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 0.5 microM; Ki = 0.2 microM) [1]
Affected Drug/Substrate Amantinin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation MK-571 inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 0.3 microM) [1]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation MK-571 inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Mitoxantrone Approved Drug
DT Modulation Mitoxantrone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Mitoxantrone inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
DT Modulation Mitoxantrone inhibits the activity of SLCO1B3 [14]
Exogenous Factor Montelukast Approved Drug
DT Modulation Montelukast inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 15 microM) [1]
Affected Drug/Substrate Amantinin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Montelukast inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 0.5 microM) [1]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
Exogenous Factor Sincalide Investigative Drug
DT Modulation Sincalide inhibits the transportation of Amantinin by SLCO1B3 (IC50 = 10 microM) [1]
Affected Drug/Substrate Amantinin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OATP1B3
DT Modulation Sincalide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Sildenafil Approved Drug
DT Modulation Sildenafil inhibits the transportation of Bosentan by SLCO1B3 (IC50 = 4 microM) [2]
Affected Drug/Substrate Bosentan Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B1
DT Modulation Sildenafil inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Repaglinide Approved Drug
DT Modulation Repaglinide inhibits the transportation of Bromsulphthalein by SLCO1B3 (IC50 = 5.6 microM) [15]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Repaglinide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Rifamycin SV Approved Drug
DT Modulation Rifamycin SV inhibits the transportation of Bromsulphthalein by SLCO1B3 (Ki = 3 microM) [5]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Oocytes-OATP1B3
DT Modulation Rifamycin SV inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Cigarette smoke condensate Natural Product
DT Modulation Cigarette smoke condensate inhibits the transportation of Cholecystokinin octapeptide sulphated by SLCO1B3 (IC50 = 7.6 microM) [16]
Affected Drug/Substrate Cholecystokinin octapeptide sulphated Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-OATP1B3
DT Modulation Cigarette smoke condensate inhibits the activity of SLCO1B3 (IC50 = 7.6 microM) [19]
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Amprenavir Approved Drug
DT Modulation Amprenavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 19.1 microM; Ki = 13.1 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Amprenavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Atazanavir Approved Drug
DT Modulation Atazanavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 3 microM; Ki = 2 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Atazanavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Digoxin Approved Drug
DT Modulation Digoxin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 1 microM; Ki = 0.7 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Digoxin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Indinavir Approved Drug
DT Modulation Indinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 12.3 microM; Ki = 8.5 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Indinavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Lopinavir Approved Drug
DT Modulation Lopinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 2 microM; Ki = 1.4 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Lopinavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ritonavir Approved Drug
DT Modulation Ritonavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 3.6 microM; Ki = 2.5 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Ritonavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Saquinavir Approved Drug
DT Modulation Saquinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 4.1 microM; Ki = 2.8 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Saquinavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Estradiol Approved Drug
DT Modulation Estradiol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 12.9 microM) [4]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Estradiol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Mifepristone Approved Drug
DT Modulation Mifepristone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 5.3 microM) [4]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
DT Modulation Mifepristone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fexofenadine Approved Drug
DT Modulation Fexofenadine inhibits the transportation of Estrone sulfate by SLCO1B3 (Ki = 205 microM) [17]
Affected Drug/Substrate Estrone sulfate Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Fexofenadine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Probenecid Approved Drug
DT Modulation Probenecid inhibits the transportation of Fexofenadine by SLCO1B3 (Ki = 130 microM) [18]
Affected Drug/Substrate Fexofenadine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Probenecid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Probenecid inhibits the transporation of ginkolide B by SLCO1B3 [24]
Affected Drug/Substrate Ginkgolide B Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)
Exogenous Factor Diclofenac Approved Drug
DT Modulation Diclofenac inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Diclofenac inhibits the activity of SLCO1B3 [21]
Exogenous Factor Doxorubicin Approved Drug
DT Modulation Doxorubicin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Doxorubicin inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Etoposide Approved Drug
DT Modulation Etoposide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Etoposide inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Irinotecan Approved Drug
DT Modulation Irinotecan inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Irinotecan inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Tamoxifen Approved Drug
DT Modulation Tamoxifen inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Tamoxifen inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Vinblastine Approved Drug
DT Modulation Vinblastine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Vinblastine inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Vincristine Approved Drug
DT Modulation Vincristine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
DT Modulation Vincristine inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Green tea Natural Product
DT Modulation Green tea inhibits the transportation of Atorvastatin by SLCO1B3 [20]
Affected Drug/Substrate Atorvastatin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-OATP1B3
DT Modulation Green tea inhibits the transportation of Bromosulfophtalein by SLCO1B3 [20]
Affected Drug/Substrate Bromosulfophtalein Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-OATP1B3
Exogenous Factor Decitabine Approved Drug
DT Modulation Decitabine inhibits DNA methyltransferase, which then enhances the expression of SLCO1B3 via downregulating the promoter hypermethylation level [22]
Cell System Human enterocyte-like 2 cell (Caco-2)
Exogenous Factor Darunavir Approved Drug
DT Modulation Darunavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B3 (IC50 = 4.8 microM; Ki = 3.3 microM) [3]
Affected Drug/Substrate Cholyl-glycylamido-fluorescein Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
Exogenous Factor Silybin A Natural Product
DT Modulation Silybin A inhibits the transportation of Estradiol-17-glucuronide by SLCO1B3 (IC50 = 2.7 microM) [23]
Affected Drug/Substrate Estradiol-17-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Silybin B Natural Product
DT Modulation Silybin B inhibits the transportation of Estradiol-17-glucuronide by SLCO1B3 (IC50 = 5 microM) [23]
Affected Drug/Substrate Estradiol-17-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Silychristin Natural Product
DT Modulation Silychristin inhibits the transportation of Estradiol-17-glucuronide by SLCO1B3 (IC50 = 36.4 microM) [23]
Affected Drug/Substrate Estradiol-17-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Lithocholate Investigative Drug
DT Modulation Lithocholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 6.8 microM) [4]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
Exogenous Factor Troglitazone Approved Drug
DT Modulation Troglitazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 (IC50 = 15.7 microM) [4]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
Exogenous Factor Silibinin dihemisuccinate Natural Product
DT Modulation Silibinin dihemisuccinate inhibits the transportation of H-amanitin by SLCO1B3 (IC50 = 1 microM; Ki = 2.1 microM) [1]
Affected Drug/Substrate H-amanitin Modulation Type Inhibition
Cell System Madin darby canine kidney strain II cell line (MDCKII)-OATP1B3
Exogenous Factor Estrone sulfate Investigative Drug
DT Modulation Estrone sulfate inhibits the transportation of Sincalide by SLCO1B3 (IC50 = 97.1 microM) [25]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Telaprevir Approved Drug
DT Modulation Telaprevir inhibits the activity of SLCO1B3 (IC50 = 0.0068 microM) [26]
Exogenous Factor Boceprevir Approved Drug
DT Modulation Boceprevir inhibits the activity of SLCO1B3 (IC50 = 4.9 microM) [27]
Exogenous Factor Mesalazine Approved Drug
DT Modulation Mesalazine inhibits the transportation of Bromsulphthalein by SLCO1B3 [28]
Affected Drug/Substrate Bromsulphthalein Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Acarbose Approved Drug
DT Modulation Acarbose inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Acyclovir Approved Drug
DT Modulation Acyclovir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Allopurinol Approved Drug
DT Modulation Allopurinol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Amantadine Approved Drug
DT Modulation Amantadine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Amitriptyline Approved Drug
DT Modulation Amitriptyline inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Amodiaquine Approved Drug
DT Modulation Amodiaquine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Atenolol Approved Drug
DT Modulation Atenolol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Atomoxetine Approved Drug
DT Modulation Atomoxetine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Atorvastatin Approved Drug
DT Modulation Atorvastatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Benzbromarone Approved Drug
DT Modulation Benzbromarone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Bestatin Approved Drug
DT Modulation Bestatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Budesonide Approved Drug
DT Modulation Budesonide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Bupropion Approved Drug
DT Modulation Bupropion inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Buspirone Approved Drug
DT Modulation Buspirone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Caffeine Approved Drug
DT Modulation Caffeine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Candesartan Approved Drug
DT Modulation Candesartan inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Captopril Approved Drug
DT Modulation Captopril inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Carbamazepine Approved Drug
DT Modulation Carbamazepine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Cefadroxil Approved Drug
DT Modulation Cefadroxil inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Cefamandole Approved Drug
DT Modulation Cefamandole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Celecoxib Approved Drug
DT Modulation Celecoxib inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Cerivastatin Approved Drug
DT Modulation Cerivastatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Cetirizine Approved Drug
DT Modulation Cetirizine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Chloroquine Approved Drug
DT Modulation Chloroquine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Chlorpromazine Approved Drug
DT Modulation Chlorpromazine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Chlorprothixene Approved Drug
DT Modulation Chlorprothixene inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Chlorzoxazone Approved Drug
DT Modulation Chlorzoxazone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Cholic acid Approved Drug
DT Modulation Cholic acid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Cimetidine Approved Drug
DT Modulation Cimetidine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Clarithromycin Approved Drug
DT Modulation Clarithromycin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Clotrimazole Approved Drug
DT Modulation Clotrimazole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Colchicine Approved Drug
DT Modulation Colchicine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Desipramine Approved Drug
DT Modulation Desipramine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Dexamethasone Approved Drug
DT Modulation Dexamethasone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Dextromethorphan Approved Drug
DT Modulation Dextromethorphan inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Diazepam Approved Drug
DT Modulation Diazepam inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Diethylstilbestrol Approved Drug
DT Modulation Diethylstilbestrol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Diltiazem Approved Drug
DT Modulation Diltiazem inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Dipyridamole Approved Drug
DT Modulation Dipyridamole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Disopyramide Approved Drug
DT Modulation Disopyramide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Disulfiram Approved Drug
DT Modulation Disulfiram inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Dofetilide Approved Drug
DT Modulation Dofetilide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Doxazosin Approved Drug
DT Modulation Doxazosin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Efavirenz Approved Drug
DT Modulation Efavirenz inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Eletriptan Approved Drug
DT Modulation Eletriptan inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Emtricitabine Approved Drug
DT Modulation Emtricitabine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Enalapril Approved Drug
DT Modulation Enalapril inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Erlotinib Approved Drug
DT Modulation Erlotinib inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Erythromycin Approved Drug
DT Modulation Erythromycin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ezetimibe Approved Drug
DT Modulation Ezetimibe inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Felodipine Approved Drug
DT Modulation Felodipine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fenofibrate Approved Drug
DT Modulation Fenofibrate inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fentanyl Approved Drug
DT Modulation Fentanyl inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fluconazole Approved Drug
DT Modulation Fluconazole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fluoxetine Approved Drug
DT Modulation Fluoxetine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Flutamide Approved Drug
DT Modulation Flutamide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fluvastatin Approved Drug
DT Modulation Fluvastatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fluvoxamine Approved Drug
DT Modulation Fluvoxamine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Furosemide Approved Drug
DT Modulation Furosemide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Gemfibrozil Approved Drug
DT Modulation Gemfibrozil inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Glibenclamide Approved Drug
DT Modulation Glibenclamide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Glipizide Approved Drug
DT Modulation Glipizide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ibuprofen Approved Drug
DT Modulation Ibuprofen inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Imipramine Approved Drug
DT Modulation Imipramine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Indocyanine green Approved Drug
DT Modulation Indocyanine green inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Indomethacin Approved Drug
DT Modulation Indomethacin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Isoniazid Approved Drug
DT Modulation Isoniazid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Isradipine Approved Drug
DT Modulation Isradipine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ivermectin Approved Drug
DT Modulation Ivermectin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ketoconazole Approved Drug
DT Modulation Ketoconazole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Lamotrigine Approved Drug
DT Modulation Lamotrigine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Lansoprazole Approved Drug
DT Modulation Lansoprazole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor L-carnitine Approved Drug
DT Modulation L-carnitine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Levofloxacin Approved Drug
DT Modulation Levofloxacin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Levothyroxine Approved Drug
DT Modulation Levothyroxine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Lisinopril Approved Drug
DT Modulation Lisinopril inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Loperamide Approved Drug
DT Modulation Loperamide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Loratadine Approved Drug
DT Modulation Loratadine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Lovastatin Approved Drug
DT Modulation Lovastatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Mephenytoin Approved Drug
DT Modulation Mephenytoin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Metformin Approved Drug
DT Modulation Metformin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Methotrexate Approved Drug
DT Modulation Methotrexate inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Methoxsalen Approved Drug
DT Modulation Methoxsalen inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Metoprolol Approved Drug
DT Modulation Metoprolol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Midazolam Approved Drug
DT Modulation Midazolam inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Moclobemide Approved Drug
DT Modulation Moclobemide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Nefazodone Approved Drug
DT Modulation Nefazodone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Nelfinavir Approved Drug
DT Modulation Nelfinavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Nicardipine Approved Drug
DT Modulation Nicardipine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Nicotine Approved Drug
DT Modulation Nicotine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Nifedipine Approved Drug
DT Modulation Nifedipine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Nitrofurantoin Approved Drug
DT Modulation Nitrofurantoin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Novobiocin Approved Drug
DT Modulation Novobiocin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Nystatin Approved Drug
DT Modulation Nystatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Olmesartan medoxomil Approved Drug
DT Modulation Olmesartan medoxomil inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Omeprazole Approved Drug
DT Modulation Omeprazole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ondansetron Approved Drug
DT Modulation Ondansetron inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ouabain Approved Drug
DT Modulation Ouabain inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Pantoprazole Approved Drug
DT Modulation Pantoprazole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Paroxetine Approved Drug
DT Modulation Paroxetine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Phenobarbital Approved Drug
DT Modulation Phenobarbital inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Phenylbutazone Approved Drug
DT Modulation Phenylbutazone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Phenytoin Approved Drug
DT Modulation Phenytoin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Pilsicainide Approved Drug
DT Modulation Pilsicainide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Pindolol Approved Drug
DT Modulation Pindolol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Pioglitazone Approved Drug
DT Modulation Pioglitazone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Piroxicam Approved Drug
DT Modulation Piroxicam inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Pravastatin Approved Drug
DT Modulation Pravastatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Prazosin Approved Drug
DT Modulation Prazosin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Prednisolone Approved Drug
DT Modulation Prednisolone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Procainamide Approved Drug
DT Modulation Procainamide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Progesterone Approved Drug
DT Modulation Progesterone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Propranolol Approved Drug
DT Modulation Propranolol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Quercetin Approved Drug
DT Modulation Quercetin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Quinine Approved Drug
DT Modulation Quinine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ranolazine Approved Drug
DT Modulation Ranolazine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Reserpine Approved Drug
DT Modulation Reserpine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Rosuvastatin Approved Drug
DT Modulation Rosuvastatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Sanguinarine Approved Drug
DT Modulation Sanguinarine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Simvastatin Approved Drug
DT Modulation Simvastatin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Sotalol Approved Drug
DT Modulation Sotalol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Spironolactone Approved Drug
DT Modulation Spironolactone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Sulfaphenazole Approved Drug
DT Modulation Sulfaphenazole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Sulfasalazine Approved Drug
DT Modulation Sulfasalazine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Telmisartan Approved Drug
DT Modulation Telmisartan inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Tenofovir Approved Drug
DT Modulation Tenofovir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Testosterone Approved Drug
DT Modulation Testosterone inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Tetracycline Approved Drug
DT Modulation Tetracycline inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Theophylline Approved Drug
DT Modulation Theophylline inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Thioridazine Approved Drug
DT Modulation Thioridazine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Thiotepa Approved Drug
DT Modulation Thiotepa inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Ticlopidine Approved Drug
DT Modulation Ticlopidine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Tipranavir Approved Drug
DT Modulation Tipranavir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Tolbutamide Approved Drug
DT Modulation Tolbutamide inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Topotecan Approved Drug
DT Modulation Topotecan inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Triazolam Approved Drug
DT Modulation Triazolam inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Trimethoprim Approved Drug
DT Modulation Trimethoprim inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Valacyclovir Approved Drug
DT Modulation Valacyclovir inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Valproic Acid Approved Drug
DT Modulation Valproic Acid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Valsartan Approved Drug
DT Modulation Valsartan inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Varenicline Approved Drug
DT Modulation Varenicline inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Verapamil Approved Drug
DT Modulation Verapamil inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Warfarin Approved Drug
DT Modulation Warfarin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Zidovudine Approved Drug
DT Modulation Zidovudine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Linagliptin Approved Drug
DT Modulation Linagliptin inhibits the transportation of Sincalide by SLCO1B3 [7]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Astemizole Drug Withdrawn
DT Modulation Astemizole inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Baicalin Discontinued Drug
DT Modulation Baicalin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Benzylpenicillin Drug in Phase 3 Trial
DT Modulation Benzylpenicillin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Berberine Drug in Phase 4 Trial
DT Modulation Berberine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Elacridar Discontinued Drug
DT Modulation Elacridar inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Fendiline Drug Withdrawn
DT Modulation Fendiline inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Genistein Drug in Phase 2 Trial
DT Modulation Genistein inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Glycyrrhizin Drug in Phase 3 Trial
DT Modulation Glycyrrhizin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Naringenin Drug in Phase 1 Trial
DT Modulation Naringenin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Phenacetin Drug Withdrawn
DT Modulation Phenacetin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Phenformin Drug Withdrawn
DT Modulation Phenformin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Sodium taurocholate Drug in Phase 1/2 Trial
DT Modulation Sodium taurocholate inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Terfenadine Drug Withdrawn
DT Modulation Terfenadine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Valspodar Discontinued Drug
DT Modulation Valspodar inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Silibinin Drug in Phase 2/3 Trial
DT Modulation Silibinin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 [23]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Aminohippuric acid Investigative Drug
DT Modulation Aminohippuric acid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Chelerythrine Investigative Drug
DT Modulation Chelerythrine inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Coumarin Investigative Drug
DT Modulation Coumarin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Coumestrol Investigative Drug
DT Modulation Coumestrol inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Daidzein Investigative Drug
DT Modulation Daidzein inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Glycochenodeoxycholic acid Investigative Drug
DT Modulation Glycochenodeoxycholic acid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Glycocholic acid Investigative Drug
DT Modulation Glycocholic acid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Glycodeoxycholic acid Investigative Drug
DT Modulation Glycodeoxycholic acid inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Morin Investigative Drug
DT Modulation Morin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Naringin Investigative Drug
DT Modulation Naringin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Phalloidin Investigative Drug
DT Modulation Phalloidin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Taurochenodeoxycholate Investigative Drug
DT Modulation Taurochenodeoxycholate inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Tetraethylammonium Investigative Drug
DT Modulation Tetraethylammonium inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B3 [6]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Silymarin flavolignans Natural Product
DT Modulation Silymarin flavolignans inhibits the transportation of Estradiol-17-glucuronide by SLCO1B3 [23]
Affected Drug/Substrate Estradiol-17-glucuronide Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor Eltrombopag Approved Drug
DT Modulation Eltrombopag inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B3 [13]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Exogenous Factor Chlorambucil Approved Drug
DT Modulation Chlorambucil inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Prednisone Approved Drug
DT Modulation Prednisone inhibits the transportation of Sincalide by SLCO1B3 [9]
Affected Drug/Substrate Sincalide Modulation Type Inhibition
Exogenous Factor Carfilzomib Approved Drug
DT Modulation Carfilzomib inhibits the activity of SLCO1B3 [29]
Cell System Human embryonic kidney 293 cells (HEK293)-OATP1B3
Exogenous Factor (-)-epicatechin-3-gallate Natural Product
DT Modulation (-)-epicatechin-3-gallate inhibits the activity of SLCO1B3 in a concentration-dependent way [30]
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
Exogenous Factor Mix silybin A silybin B Natural Product
DT Modulation Mix silybin A silybin B inhibits the activity of SLCO1B3 [31]
Cell System Chinese hamster ovary (CHO) cells-OATP1B3
Exogenous Factor Dactinomycin Approved Drug
DT Modulation Dactinomycin inhibits the activity of SLCO1B3 [14]
Exogenous Factor Docetaxel Approved Drug
DT Modulation Docetaxel inhibits the activity of SLCO1B3 [14]
Exogenous Factor Glecaprevir Approved Drug
DT Modulation Glecaprevir inhibits the activity of SLCO1B3 [32]
Exogenous Factor Itraconazole Approved Drug
DT Modulation Itraconazole inhibits the activity of SLCO1B3 [33]
Exogenous Factor Letermovir Approved Drug
DT Modulation Letermovir inhibits the activity of SLCO1B3 [34]
Exogenous Factor Rifaximin Approved Drug
DT Modulation Rifaximin inhibits the activity of SLCO1B3 [35]
Exogenous Factor Selexipag Approved Drug
DT Modulation Selexipag inhibits the activity of SLCO1B3 [36]
Exogenous Factor Telithromycin Approved Drug
DT Modulation Telithromycin inhibits the activity of SLCO1B3 [37]
Exogenous Factor Asunaprevir Drug in Phase 3 Trial
DT Modulation Asunaprevir inhibits the activity of SLCO1B3 [38]
Exogenous Factor Estradiol-17beta-glucuronide Investigative Drug
DT Modulation Estradiol-17beta-glucuronide modulates the activity of SLCO1B3 [39]
References
1 Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
2 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
3 Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010 Mar;40(3):163-76.
4 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
5 Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
6 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
7 Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos. 2013 Jan;41(1):149-58.
8 Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res. 2008 Aug;25(8):1851-60.
9 Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
10 High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res. 2011 Jan 15;17(2):294-301.
11 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
12 Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans. Drug Metab Dispos. 2013 May;41(5):994-1003.
13 Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
14 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
15 Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008 Jun;57(6):1463-9.
16 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
17 Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81.
18 Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos. 2006 May;34(5):743-7.
19 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
20 Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
21 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
22 Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res. 2013 Nov;30(11):2880-90.
23 Interaction of silymarin flavonolignans with organic anion-transporting polypeptides. Drug Metab Dispos. 2013 May;41(5):958-65.
24 The potential drug-drug interactions of ginkgolide B mediated by renal transporters. Phytother Res. 2015 May;29(5):662-7.
25 Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
26 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
27 In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos. 2013 Mar;41(3):668-81.
28 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
29 Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner. PLoS One. 2017 Nov 6;12(11):e0186924.
30 Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos. 2011 May;39(5):920-6.
31 Hepatocellular organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin. Drug Metab Dispos. 2013 Aug;41(8):1522-8.
32 Translation of in vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. J Pharmacol Exp Ther. 2019 Jun 5. pii: jpet.119.256966.
33 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
34 Australisn product information - PREVYMIS (Letermovir)
35 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG02907)
36 The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag. Xenobiotica. 2018 Jul;48(7):704-719.
37 The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007 May;35(5):779-86.
38 FDA Drug Development and Drug Interactions
39 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1221).

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.